
Bristol-Myers Squibb Co
NYSE:BMY

Intrinsic Value
The intrinsic value of one
BMY
stock under the Base Case scenario is
70.85
USD.
Compared to the current market price of 50 USD,
Bristol-Myers Squibb Co
is
Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Bristol-Myers Squibb Co
Fundamental Analysis

Heightened patent-expiration risk and revenue concentration around key drugs like Revlimid and Eliquis could sharply reduce Bristol-Myers Squibb’s cash flows, limiting its ability to fund pipeline development.
Bristol-Myers Squibb holds a leading position in immuno-oncology with proven blockbusters like Opdivo and Yervoy, providing a strong base of recurring revenue and brand recognition.

Revenue & Expenses Breakdown
Bristol-Myers Squibb Co
Balance Sheet Decomposition
Bristol-Myers Squibb Co
Current Assets | 29.8B |
Cash & Short-Term Investments | 10.9B |
Receivables | 14.4B |
Other Current Assets | 4.5B |
Non-Current Assets | 62.8B |
Long-Term Investments | 2.1B |
PP&E | 8.4B |
Intangibles | 45B |
Other Non-Current Assets | 7.4B |
Free Cash Flow Analysis
Bristol-Myers Squibb Co
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Bristol-Myers Squibb Co
Revenue
|
48.3B
USD
|
Cost of Revenue
|
-11.9B
USD
|
Gross Profit
|
36.4B
USD
|
Operating Expenses
|
-24.8B
USD
|
Operating Income
|
11.5B
USD
|
Other Expenses
|
-20.5B
USD
|
Net Income
|
-8.9B
USD
|
BMY Profitability Score
Profitability Due Diligence
Bristol-Myers Squibb Co's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Score
Bristol-Myers Squibb Co's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
BMY Solvency Score
Solvency Due Diligence
Bristol-Myers Squibb Co's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Score
Bristol-Myers Squibb Co's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMY Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for
BMY
is 60.92 USD
with a low forecast of 33.43 USD and a high forecast of 73.5 USD.
Dividends
Current shareholder yield for BMY is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BMY
stock under the Base Case scenario is
70.85
USD.
Compared to the current market price of 50 USD,
Bristol-Myers Squibb Co
is
Undervalued by 29%.